Golestan Research Center of Psychiatry (GRCP), Golestan University of Medical Sciences, Gorgan, Iran.
BSN, Student research committee, Golestan University of Medical Sciences, Gorgan, Iran.
BMC Psychiatry. 2022 Nov 4;22(1):681. doi: 10.1186/s12888-022-04246-x.
Schizophrenia is a devastating condition characterized by frequent recurrences, cognitive decline, and emotional and functional disabilities. This condition includes positive and negative symptoms and cognitive impairments resistant to drug treatment. According to studies, many biomarkers can affect this disorder. However, there is little information about vitamin D and homocysteine levels in patients with disease complications. We aimed to investigate this relationship in schizophrenia.
In this case-control study, 33 patients with schizophrenia and 33 healthy individuals were enrolled from Golestan, the north of Iran, in 2021. Blood samples were taken from all participants to assess vitamin D and homocysteine serum levels. In addition, schizophrenic patients completed the Positive And Negative Syndrome Scale (PANSS) and Simpson-Angus Extrapyramidal Side Effects Scale (SAS). Data analysis was performed at a significance level of 0.05 using SPSS 16 software.
Of the 66 participants, 66.7% had vitamin D deficiency, and 71.2% had normal homocysteine levels. However, the serum level of vitamin D was lower in schizophrenic patients than in controls (p = 0.035), and serum homocysteine levels were higher in the schizophrenic group than in controls (p < 0.001). Vitamin D levels in patients with schizophrenia were significantly correlated with the overall assessment of extrapyramidal symptoms (r = 0.35, p = 0.04). However, no significant relationship existed between vitamin D and homocysteine levels and PANSS results (p > 0.05).
Serum levels of vitamin D and homocysteine were significantly lower and higher in schizophrenic patients than in the control group. Improvement of extrapyramidal symptoms in schizophrenic patients had a direct and significant relationship with serum vitamin D.
精神分裂症是一种严重的疾病，其特征是频繁复发、认知能力下降以及情感和功能障碍。这种疾病包括阳性和阴性症状以及对药物治疗有抵抗力的认知障碍。根据研究，许多生物标志物会影响这种疾病。然而，关于患有疾病并发症的患者的维生素 D 和同型半胱氨酸水平的信息很少。我们旨在研究这种关系。
在这项病例对照研究中，2021 年从伊朗北部戈勒斯坦招募了 33 名精神分裂症患者和 33 名健康个体。从所有参与者中抽取血液样本，以评估维生素 D 和同型半胱氨酸血清水平。此外，精神分裂症患者完成阳性和阴性综合征量表（PANSS）和辛普森-安格斯锥体外系副作用量表（SAS）。使用 SPSS 16 软件在 0.05 的显着性水平下进行数据分析。
在 66 名参与者中，66.7%的人存在维生素 D 缺乏，71.2%的人同型半胱氨酸水平正常。然而，与对照组相比，精神分裂症患者的血清维生素 D 水平较低（p=0.035），而精神分裂症组的血清同型半胱氨酸水平较高（p<0.001）。精神分裂症患者的维生素 D 水平与锥体外系症状的总体评估显著相关（r=0.35，p=0.04）。然而，维生素 D 和同型半胱氨酸水平与 PANSS 结果之间没有显著关系（p>0.05）。
与对照组相比，精神分裂症患者的血清维生素 D 和同型半胱氨酸水平显著降低和升高。精神分裂症患者锥体外系症状的改善与血清维生素 D 有直接显著关系。
